CAMP · Camp4 Therapeutics Corp
$3.90
-0.14 (-3.47%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$245.37M
Shares
62.75M
Volume · Oct 1
994.73K
Avg daily vol (3M)
241.07K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.04
Open$3.96
Day$3.86–4.09
52W close$2.90–7.13
Avg vol 30d281K
Short int993K · 1.6% float · 3.6d
Short vol94%
Last earningsNov 21, 2024
DataOct 2024–Sep 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
call held Nov 21, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.22M
Trailing 12 months
Net income (TTM)
−$107.24M
Trailing 12 months
Revenue growth YoY
+18.8%
Year over year
Operating margin
-1,254.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$86.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+187.4%
Year over year · more shares
Price change (1Y)
+34.7%
Trailing year
Short interest
1.6%
Latest settlement · 3.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
−10%
trailing
YTD return
−34%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+30% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$2.4M over 90 days · 33% sells
Short interest
Falling
1.58% of float · ▼ -16.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 1-yr high, broad support
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+437%
Y/Y
EPS growth
+76%
Y/Y
Free cash flow
$-29.8M
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2020
Cash basis tax rate
· remainder of this fiscal year
3.5% – 5.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+30% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$2.4M over 90 days · 33% sells
Short interest
Falling
1.58% of float · ▼ -16.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 27%
Range high $7
vs 200-day avg -10%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAMP
this stock
Camp4 Therapeutics Corp
|
$245.37M | -34.1% | +436.5% | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAMP | +8.6% | +6.6% | -10.0% | +2.0% | -34.1% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +9.3% | +6.5% | -22.2% | +2.6% | -45.9% |